Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anavex Life Sciences has received approval from the German regulatory health authority, BfArM, to conduct Phase I clinical trial of Anavex-2-73 including tests in healthy volunteers.
Subscribe to our email newsletter
Anavex will evaluate the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics in the Phase I trial.
Anavex-2-73 represents a new class of wholly owned compounds that act through sigma-1 receptor agonism, and muscarinic, cholinergic effects and modulation of endoplasmic reticulum stress leading to a series of intracellular effects to modify ion channel signalling at the mitochondrial level.
ANAVEX 2-73 is the first of a new class of oral, disease-modifying drugs being studied to treat Alzheimer’s disease rather than treating its symptoms.
The Phase I trial of ANAVEX 2-73 will be conducted in collaboration with ABX-CRO and the University of Dresden in Germany.